Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.

Iacobucci I, Di Rorà AG, Falzacappa MV, Agostinelli C, Derenzini E, Ferrari A, Papayannidis C, Lonetti A, Righi S, Imbrogno E, Pomella S, Venturi C, Guadagnuolo V, Cattina F, Ottaviani E, Abbenante MC, Vitale A, Elia L, Russo D, Zinzani PL, Pileri S, Pelicci PG, Martinelli G.

J Hematol Oncol. 2015 Nov 5;8:125. doi: 10.1186/s13045-015-0206-5.

2.

Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma.

Derenzini E, Iacobucci I, Agostinelli C, Imbrogno E, Storlazzi CT, L Abbate A, Casadei B, Ferrari A, Di Rora AG, Martinelli G, Pileri S, Zinzani PL.

Exp Hematol Oncol. 2015 Aug 27;4:24. doi: 10.1186/s40164-015-0019-9.

3.

IFI16 Expression Is Related to Selected Transcription Factors during B-Cell Differentiation.

Piccaluga PP, Agostinelli C, Fuligni F, Righi S, Tripodo C, Re MC, Clò A, Miserocchi A, Morini S, Gariglio M, Ferri GG, Rinaldi-Ceroni A, Piccin O, De Andrea M, Pileri SA, Landolfo S, Gibellini D.

J Immunol Res. 2015;2015:747645. doi: 10.1155/2015/747645.

4.

Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.

Pizzi M, Piazza F, Agostinelli C, Fuligni F, Benvenuti P, Mandato E, Casellato A, Rugge M, Semenzato G, Pileri SA.

Oncotarget. 2015 Mar 30;6(9):6544-52.

5.

Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.

Alinari L, Mahasenan KV, Yan F, Karkhanis V, Chung JH, Smith EM, Quinion C, Smith PL, Kim L, Patton JT, Lapalombella R, Yu B, Wu Y, Roy S, De Leo A, Pileri S, Agostinelli C, Ayers L, Bradner JE, Chen-Kiang S, Elemento O, Motiwala T, Majumder S, Byrd JC, Jacob S, Sif S, Li C, Baiocchi RA.

Blood. 2015 Apr 16;125(16):2530-43. doi: 10.1182/blood-2014-12-619783.

6.

Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.

Derenzini E, Agostinelli C, Imbrogno E, Iacobucci I, Casadei B, Brighenti E, Righi S, Fuligni F, Ghelli Luserna Di Rorà A, Ferrari A, Martinelli G, Pileri S, Zinzani PL.

Oncotarget. 2015 Mar 30;6(9):6553-69.

7.

Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified.

Laginestra MA, Piccaluga PP, Fuligni F, Rossi M, Agostinelli C, Righi S, Sapienza MR, Motta G, Gazzola A, Mannu C, Sabattini E, Bacci F, Tabanelli V, Sacchetti CA, Barrese TZ, Etebari M, Melle F, Clò A, Gibellini D, Tripodo C, Inghirami G, Croce CM, Pileri SA.

Blood Cancer J. 2014 Nov 7;4:259. doi: 10.1038/bcj.2014.78.

8.

Pathobiology of hodgkin lymphoma.

Agostinelli C, Pileri S.

Mediterr J Hematol Infect Dis. 2014 Jun 5;6(1):e2014040. doi: 10.4084/MJHID.2014.040. Review.

9.

Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma.

Pallotti MC, Nannini M, Agostinelli C, Leoni S, Scioscio VD, Mandrioli A, Lolli C, Saponara M, Pileri S, Bolondi L, Biasco G, Pantaleo MA.

World J Gastroenterol. 2014 Jun 14;20(22):7049-54. doi: 10.3748/wjg.v20.i22.7049.

10.

FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities.

L'Abbate A, Lo Cunsolo C, Macrì E, Iuzzolino P, Mecucci C, Doglioni C, Coco M, Muscarella LA, Salati S, Tagliafico E, Minoia C, De Tullio G, Guarini A, Testoni N, Agostinelli C, Storlazzi CT.

BMC Cancer. 2014 Jun 3;14:396. doi: 10.1186/1471-2407-14-396.

11.

The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies.

Gazzola A, Mannu C, Rossi M, Laginestra MA, Sapienza MR, Fuligni F, Etebari M, Melle F, Sabattini E, Agostinelli C, Bacci F, Sagramoso Sacchetti CA, Pileri SA, Piccaluga PP.

Ther Adv Hematol. 2014 Apr;5(2):35-47. doi: 10.1177/2040620713519729. Review. Erratum in: Ther Adv Hematol. 2014 Oct;5(5):181.

12.

Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition.

Sapienza MR, Fuligni F, Agostinelli C, Tripodo C, Righi S, Laginestra MA, Pileri A Jr, Mancini M, Rossi M, Ricci F, Gazzola A, Melle F, Mannu C, Ulbar F, Arpinati M, Paulli M, Maeda T, Gibellini D, Pagano L, Pimpinelli N, Santucci M, Cerroni L, Croce CM, Facchetti F, Piccaluga PP, Pileri SA; AIRC 5xMille consortium ‘Genetics-driven targeted management of lymphoid malignancies and the Italian Registry on Blastic Plasmacytoid Dendritic Cell Neoplasm..

Leukemia. 2014 Aug;28(8):1606-16. doi: 10.1038/leu.2014.64.

13.

Hsa-miR-15a and Hsa-miR-16-1 expression is not related to proliferation centers abundance and other prognostic factors in chronic lymphocytic leukemia.

Rossi M, Fuligni F, Ciccone M, Agostinelli C, Righi S, Luciani M, Laginestra MA, Rigolin GM, Sapienza MR, Gazzola A, Mannu C, Cuneo A, Pileri S, Piccaluga PP.

Biomed Res Int. 2013;2013:715391. doi: 10.1155/2013/715391.

14.

Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.

Chung J, Karkhanis V, Tae S, Yan F, Smith P, Ayers LW, Agostinelli C, Pileri S, Denis GV, Baiocchi RA, Sif S.

J Biol Chem. 2013 Dec 6;288(49):35534-47. doi: 10.1074/jbc.M113.510669.

15.

CD30 expression in peripheral T-cell lymphomas.

Sabattini E, Pizzi M, Tabanelli V, Baldin P, Sacchetti CS, Agostinelli C, Zinzani PL, Pileri SA.

Haematologica. 2013 Aug;98(8):e81-2. doi: 10.3324/haematol.2013.084913. Review. No abstract available.

16.

GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers.

Hartmann S, Agostinelli C, Diener J, Döring C, Fanti S, Zinzani PL, Gallamini A, Bergmann L, Pileri S, Hansmann ML.

BMC Cancer. 2012 Dec 10;12:586. doi: 10.1186/1471-2407-12-586.

17.

The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.

Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foà R, Dalla-Favera R, Pasqualucci L, Rabadan R, Gaidano G.

J Exp Med. 2012 Aug 27;209(9):1537-51. doi: 10.1084/jem.20120904.

18.

Pathobiology of ALK-negative anaplastic large cell lymphoma.

Pileri SA, Agostinelli C, Bacci F, Sabattini E, Sagramoso C, Falini B, Piccaluga PP.

Pediatr Rep. 2011 Jun 22;3 Suppl 2:e5. doi: 10.4081/pr.2011.s2.e5.

19.

Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature.

Tabanelli V, Agostinelli C, Sabattini E, Gazzola A, Bacci F, Capria S, Mannu C, Righi S, Sista MT, Meloni G, Pileri SA, Piccaluga PP.

J Med Case Rep. 2011 Jun 7;5:218. doi: 10.1186/1752-1947-5-218.

20.

Pathobiology of anaplastic large cell lymphoma.

Piccaluga PP, Gazzola A, Mannu C, Agostinelli C, Bacci F, Sabattini E, Sagramoso C, Piva R, Roncolato F, Inghirami G, Pileri SA.

Adv Hematol. 2010:345053. doi: 10.1155/2010/345053.

Items per page

Supplemental Content

Loading ...
Support Center